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Abstract 
Pharmaceutical companies in Eastern European region are facing urgent quality tools 
implementation due to fierce global competition.  The aim of this research is to provide current 
understanding of TQM in this region and provide further guidance on how to improve quality 
standards and techniques. The study follows a qualitative method and data was collected through 
5 semi-structured interviews. The study highlights that TQM in pharmaceutical industry in this 
region is not well developed. The findings shows that there is lack of senior management 
commitment to TQM principles explanation and emphasises on its importance. Additionally, 
lack of governmental influence on quality standards and budgeting problems also affects TQM 
development. Moreover, there is a believe that TQM will not influence the overall performance 
of the company in the positive manner, since the development of such quality improvement 
method has to be efficiently budgeted and under current economic and political circumstances it 
is not possible. 
 
Introduction 
In order to satisfy customers’ needs, wants and requirements, three fundamental criteria have to 
be achieved, which are quality, price and delivery (also known as ‘On-quality’, ‘On-cost’ and 
‘On-time’). While delivery and price bear a short-term effect (Hoyle, 2007), quality lasts the 
customer for the longest period (Oakland, 2014). Therefore, nowadays quality is considered as 
the most important element of company’s reputation. Research has shown that once being faced 
dissatisfaction with quality, it takes long time for organisations to regain the trust of customers 
and often can lead to loss of customers (Oakland, 2014; Chen, 2017). In research by Steenkamp 
(1990) quality is explained from two perspectives: macro level (the importance of quality for the 
country) and micro level (how quality evolves for managers). Therefore, it is important to outline 
that this research will be conducted on a micro level, since we are interested in changes of 
quality perceptions at company’s level. 
There are numerous definitions of quality due to deep interest of researchers in this area. 
Nonetheless, study conducted by Garvin (1984) in early 1980s states that the quality issue was 
not fully covered by scholars at that time, as researchers from different backgrounds (e.g. 
marketing, philosophy, economics etc.) considered quality from different perspectives. However, 
nowadays many frameworks exist that define, explore and assure quality from various angles 
(Heravizadeh, et al., 2008; Núñez et al., 2015). Porter (1980) positions quality as a product 
differentiation strategy, which lures customers and creates barriers for further competition. 
Adding to this, Ye & Mukhopadhyaya (2013) in their study suggests quality as a strategic goal 
that exists in company in order to increase the demand of products. Despite one emphasises that 
joint quality improvement leads to cost and time reduction, Chen, et al. (2012) oppose saying 
that quality excludes these factors and a new strategy of organisation – quality-time-cost-oriented 
strategy – has to be followed in order to attract consumers (Ouyang et al., 2002). At the same 
time, Juran & Godfrey (1999) add that quality affects not only the cost, but also the income of 
the company and connects this effect with customer’s satisfaction. Therefore, it is important to 
consider quality from customer’s point, as they have a significant influence on it. 
The perception of quality is not the same for an organisation and customers. According to 
research conducted by Montgomery Ward & Co. (1973), customers evaluate a product by 
‘usefulness’ and its relation to investments made, where the first element of quality evaluation is 
compliance with quality standards and the last – actions made by the company to eliminate the 
defects. In contrast, research conducted in the beginning of 21
st
 century states that nowadays the 
first element of customer satisfaction in terms of quality is accessibility (e.g. convenient parking 
slots and user friendly websites), while the last element is ability for continuous improvement, 
even if the product cannot be further improved (Brown, 2007; Mitra, 2016). Consequently, there 
is a change in quality understanding from customer’s point of view: not only the product itself 
has to be of a good quality, but also the way of receiving information about it, availability of the 
sales person, way of negotiation etc. To create such ‘Circle of satisfaction’, organisation has to 
be well organised, solid and efficient and provide satisfaction to both, customers and employees 
(Vora, 2002). Therefore, quality from the organisational point of view also has to be considered. 
By involving the whole organisation (e.g. marketing, procurement, financial etc. departments) in 
process of identifying and satisfying customer’s needs, the performance of the company also will 
be improved, since there is a belief that improvement in quality lead to advancements in 
efficiency, performance and level of income (Terziovski, et al., 1999; Mitra, 2016 ). Out of this, 
interconnection between such organisational variables as organisational structure, performance 
and strategy becomes significant for further company’s activities and highly influences the 
quality (Prajogoa & Sohalb, 2006). At the same time, the organisation also becomes an internal 
consumer of quality: in order to receive better results, the organisation itself has to produce high 
quality accomplishments and split it respectively between the departments, (e.g. report created in 
marketing department has to satisfy supply chain department etc.) in order to carry the activities 
of the company continuously (Hoyle, 2007). Consequently, it is becoming important to achieve 
high quality standards in the company itself. These achievements might happen as a result of 
TQM implementation in the company, which will support the overall company’s strategy, 
improve organisational performance, and increase the level of consumer satisfaction (Prajogoa & 
Sohalb, 2006). Psomas and Jaca (2016) measured the impact of total quality management on 
service company performance and showed that TQM factors concerning customers, employees 
and top management significantly affect the performance. 
Quality management has become one of the most significant factors of company’s success and 
competitiveness (Juran & Godfrey, 1999). Today, quality management can be defined as a 
system, which directs and controls the organisation to quality (Visser et al., 2010). In order to 
implement this managerial practice effectively, TQM principles have to be followed. The 
following scholars examined the variety of such principles as Garza-Reyes et al. (2018), Oakland 
(2014), Bhat (2010), Zaire (1991), Ghobadian & Gallear (1997), Hill & Wilkinson (1995), Keng 
Boon et al. (2005). Oakland (2014) states that effective TQM implementation can be achieved 
through the 4 Ps model. This includes planning, performance, process and people (Oakland, 
2014). Other from this framework, Bhat (2010) introduces a broader view on the implementation 
of TQM practice through the main TQM infrastructures: leadership, strategic planning, human 
resource management, process management and data and information management, as this 
function is supportive to any business. The first infrastructure is leadership: each manager as a 
leader has to act as leader for the quality in the organisation and establish quality value and goals 
(Bhat, 2010). Zairi (1994) emphasises the difference of managers and leaders in terms of first 
infrastructure. As per his studies, soft and inter-personal skills differentiate leaders from 
managers (Zairi, 1994). The second infrastructure of TQM is strategic planning, as the company 
has to set a long time strategy and quality has to be among the main objectives. Even though, 
strategic planning is believed to be among TQM infrastructures, many researchers, such as 
Srinidhi (1997), Bilich and Neto (1997) etc. believe, that today strategic planning in terms of 
TQM has evolved to a separate science, which is known as strategic quality management (SQM). 
According to Madu and Kuei (1993), the strategic quality management philosophy aims to 
provide company with sustainable competitive advantage by strengthening its quality objectives. 
The third infrastructure includes human resource management, which means that all workers 
have to be involved in TQM process so that to follow the process of continuous improvement 
inside of the company. From Flynn et al. (1994) work, which is restricted only to plants, the third 
infrastructure is described differently and called workforce management (Flynn, et al., 1994). 
The above-mentioned study states that in order to improve TQM, the employers have to be loyal 
to the company and recruit employees with task-oriented skills, ability to work in team and 
follow quality values (Flynn, et al., 1994). The fourth infrastructure is process management, as 
this process leads to delivering goods to the customers, which have to be of a high quality (Bhat, 
2010). In contrast, the study of Flynn, et al. (1994) describes process management as a 
particularly manufacturing process, which includes equipment maintenance, operational 
activities and documenting of manufacturing process (Flynn, et al., 1994). The fifth 
infrastructure is data and information management, as this function is supportive to any business 
(Bhat, 2010). In Luburić’s (2014) point of view, information is not that important as a separate 
infrastructure. Efficient decision-making process, based on logical, accurate and checked 
information is more important for TQM (Luburić, 2014). As to Zairi (1994), a different 
framework of implementing TQM is possible: TQM can be implemented through 3 aspects: 
continuous improvement, value added management and employee involvement. Other scholars 
suggest using such tools as statistical control, Six Sigma, Kaizen approach, Deming wheel 
Paretto analysis, tree decisions histograms etc. (Imeri and Kekäle, 2013). However, 
implementation of TQM principles cannot be efficient, if it is not a continuous and integrated 
process in the company, which is constantly reviewed and changed (Kia LiangTan, 1997; Ross, 
2017). 
At the same time, such scholars as Oakland (2014), Rahman & Bullock (2005) argue that not 
only ‘hard management tools’, described previously, influence effective TQM implementation. 
For instance, Rahman & Bullock (2005) emphasise that the implementation of ‘hard tools’ may 
not lead to a strong competitive advantage, if ‘soft tools’ are not implemented. At the same time, 
soft skills have a strong indirect effect on company’s activities through its influence on ‘hard 
tools’ (Rahman & Bullock, 2005). As to Oakland (2014) ‘soft tools’ are established through a 3 
Cs model: customers, communication and commitment. However, Fotopoulos and Psomas 
(2009) provides another understanding of ‘soft tools’ of TQM, which are leadership, employee 
motivation and organisational culture. Vouzas and Psychogios (2007) generalises the possible 
‘soft’ principles and identifies 9 tools, which add to the previously discussed scholars absolute 
employee involvement, endless improvement, continuous training and mentoring programmes, 
top-management backing and sustainable management style. 
 
Approaches of ‘hard’ and ‘soft’ principles while TQM implementation 
In order to implement TQM effectively, a guidance of ‘usage of hard’ and ‘soft’ TQM principles 
has to be established. Mosadeghrad (2013) states that three possible approaches of 
implementation of ‘hard’ and ‘soft’ skills exist: The first approach is called standard-based 
approach and is based on implementation of new standards in the company (e.g. ISO 9001). This 
approach provides managers with standardisation and administrative methods of control of 
employee’s activities. However, this method does not consider customer as a part of quality 
improvement plan, therefore is not believed to be effective, as it concentrates only on the 
organisational needs of the company (Mosadeghrad, 2013). Out of this, the conclusion is that 
ISO implementation in terms of quality improvement will not lead to a competitive advantage 
and has to be supported by other tools. The second possible approach is based on quality awards 
models. TQM acts as a self-assessment tool for companies and is being constantly recognised by 
different organisations that present the awards. This method motivates companies not only to 
concentrate on administrative functions and their quality, but goes beyond that. The third 
approach includes individually developed methods of TQM implementation, which can be 
applied in any industry. All of these three approaches can work as guidance of TQM 
implementation (Mosadeghrad, 2013). 
Besides the implementation of ‘hard’ and ‘soft’ principles, using different approaches, some 
circumstances might influence TQM implementation. For example, in order to hit higher results 
from TQM implementation, company has to use its capacities in full (e.g. full capacity of 
employees and training programmes from them; elimination of large slacks in manufacturing 
process in order to increase productivity by slight increase in quality indicators) (Oliveira et al. 
2017). In order to identify these slacks, employees and customers are the ones who can provide a 
feedback. Therefore, it is significantly important to have a tooled feedback system (Tan, 1997). 
 
 
Beyond TQM implementation: the analysis of TQM effectiveness 
Even though the implementation of TQM is a long-time process and most probably increases the 
competitiveness of the company overall (Youssef and Youssef, 2018; Ho, 2010), as well as 
positively influences business performance, it is significantly important to analyse the results of 
the implication of such managerial tool. The latter can be analysed by using such tools as 
Accruals and Altman Z-score (Lawson, 2008). In addition, more abstract tool, such as 
measurement of client’s satisfaction also can be used for quality improvement evaluation (Al-
Abri and Al-Balushi, 2014). These methods are favourable for evaluation of TQM 
implementation, as they do not focus on finding errors and defects, but on continuous work 
analysis for regular advancement (Elliot, 1993). Nonetheless, the above-mentioned tools are 
aimed to analyse the impact of so-called ‘hard’ TQM tools, while scholars believe that the 
middle managers in companies of any scale lack the system for measurement of ‘soft’ tools 
(Psoma et al. 2017). This lack of TQM knowledge may occur, since quite often middle managers 
confront to TQM implementation as they are not involved into this process (Dale & Cooper, 
1994). To avoid this, Dale & Cooper (1994) suggest to improve communications in the company 
and provide prove of TQM importance to middle managers from senior executives. Tan (1997) 
emphasises the importance of a teamwork concept in order to manage TQM implementation 
effectively, since in case employees are fully involved in quality process, it is likely to receive 
grounded feedbacks from them. Besides, a better understanding of connection between quality 
improvement and company’s performance is required in order to design long-time strategies with 
quality control and assurance (Mann & Kehoe, 1994).  
Importance of TQM in pharmaceutical industry 
From the beginning of 21
st
 century, quality in pharmaceutical industry became a popular field of 
studies. This is connected with introduction of Good Manufacturing Practice (GMP) by Food and 
Drug Administration (FDA) in early 2000, publishing of quality guidelines for pharmaceutical 
industry by World Health Organisation (WHO), and announcement of a set of quality 
requirements called ‘The rules governing medicinal products in the European Union’ (World 
Health Organisation, 2004; European Union, 2008). Consequently, pharmaceutical companies 
started to review their quality approaches and the interest of implementation of different quality 
techniques has risen (Woodcock, 2004). Among the techniques which are widely used in 
pharmaceutical industry such scholars as Shanley (2005), Haleem et al. (2015) highlight Six 
Sigma approach (e.g. The DMAIC model in AstraZeneca), Process Analytical Technologies (e.g. 
PAT in GlaxoSmithKline, Sanofi-Aventis), and ISO series (Shanley, 2005; Haleem, et al., 2015). 
TQM stands also among the methods of quality improvement in pharmaceutical company, but 
appears as an abstract term: a concept or a philosophy, rather than a technique (Haleem, et al., 
2015; Mosadeghrad, 2013). The implementation of any above-mentioned techniques of quality 
improvement will improve total quality in the pharmaceutical company, as well as improve the 
company’s image and reputation. However, many healthcare companies find it difficult to 
implement these tools, TQM in particular. Study conducted by Mosadeghrad (2013) emphasises 
the importance of implementation not only ‘hard’ TQM principles, but also ‘soft’ principles, 
since the superficial TQM implementation does not lead to quality improvement and might even 
lower it, causing negative impression for employees. 
Current situation of pharmaceutical industry in Eastern Europe 
In order to provide recommendations and possible best practice of TQM implementation in 
Eastern Europe, it is necessary to give a brief overview of current market situation in this region. 
This will help not only to understand Easter European market better, but also find an example of 
how TQM might be implemented under similar economic and political circumstances. 
As in PWC report (2013), emerging markets nowadays are believed to be significant influents on 
pharmaceutical arena. As an example, it is predicted that in 2016 30% of global pharmaceutical 
sales will be generated by emerging markets (PWC, 2013). However, we need to distinguish 
different types of them – there is BRICMT group (which includes Brazil, Russia, India, China, 
Mexico and Turkey) and another group which includes more mature economics – Eastern 
Europe and CIS (Common Wealth of independent States), in which this research is interested 
(PWC, 2013). This second group is believed to be lagging from BRICMT countries; furthermore, 
Eastern and Central European pharmaceutical companies are not predicted to grow significantly 
in recent future (PWC, 2013). Consequently, we can notice that despite some markets are 
believed to be emerging, all of them are growing with a different rate and significance on global 
pharmaceutical market.  
Pharmaceutical market in Eastern Europe is considerably lagging from its western counterparts. 
The underlying reasons for that is a lack of managerial development and weak governmental 
influence on this particular sector. Besides, high level of corruption and lack of cost control lead 
pharmaceutical sector in this region to a lagging position. Moreover, countries in this region have 
undergone a sequence of political and economic reforms and currently experience instability 
(Seiter, 2010). These are the common reasons which expand on Eastern Europe overall, 
however, we have to consider each country in this region separately in order to create a better 
understanding of current state of pharmaceutical market. Besides, this can provide better 
understanding of TQM development in this region and accept or doubt the results of this 
research. 
Despite negative tendency of pharmaceutical industry in this region (PWC report, 2013), 
pharmaceutical market in Eastern Europe was predicted to reach US 104.2 billion by 2016. In 
particular, such countries as Poland, Romania and Czech Republic are believed to be the most 
experienced in pharmaceutical industry and therefore attract subsidiaries of large transnational 
corporations (e.g. Zentiva, Gedeon Richter, Polpharma etc.) (CHEManager International, 2013; 
PWC, 2013). We can notice that this information is in full compliance with 3 groups of countries 
which were determined in literature review part; however, Romania was assigned to the second 
group of the countries, which means that this country is in transformation period. To analyse 
polish pharmaceutical development, we can state that it will be significantly influential in 
European pharmaceutical market in recent years, since Poland is the only country in the EU, 
which experienced growth in pre-crisis and post-crisis periods (McKinsey & Company, 2015). 
However, low rates of productivity in comparison with western countries are making Poland less 
competitive in pharmaceutical sector. In long term, it is believed that healthcare sector will 
become a prominent one for Poland, since currently the growth in this sector was 7-8% in period 
2004-2011, whilst the growth of this sector in developed Germany was only 5% (McKinsey & 
Company, 2015). If to consider the Romanian pharmaceutical market, it is expected to expand 
significantly by 2016, even though the growth will not be dramatic due to slow economic 
recovery (PR NewsWire, 2012). Romanian pharmaceutical industry is then followed by 
Slovakia. However, poor quality infrastructure and public administration are not influencing 
pharmaceutical industry positively and dragging it down (European Commission, 2015). If to 
consider Hungarian situation in pharmaceutical sector, one can notice that there is a positive 
development of it. Even though Hungarian pharmaceutical industry has a long history of 
development, currently there is a modernisation of its infrastructure and huge investments in 
R&D (Jablonski, 2007). Speaking about Slovenian pharmaceutical industry, we should state that 
this market is described as a stable one, since Slovenia has a long tradition of pharmaceutical 
manufacturing (Invest Slovenia, 2012). Local agents explain stable situation on the market by 
highly knowledgeable employees, who are involved in this sector. Moreover, the infrastructure 
of pharmaceutical sector also stimulates the development of this industry – excellent physical 
and soft infrastructure lure foreign investors to Slovenia (Invest Slovenia, 2012). In a whole, this 
region has a great number of pharmaceutical companies.  
The situation of pharmaceutical sector in the second group of countries (which includes Bulgaria, 
Latvia, Lithuania and Estonia, since Romania was determined as in transition period in terms of 
pharmaceutical industry development) can be described as a stable. In Bulgaria, pharmaceutical 
sector is believed to be one of the fastest growing sectors for the economy of the country. The 
production is believed to be of a high quality, whilst the prices are competitive. Moreover, 
Bulgarian pharmaceutical sector was not influenced negatively be economic crisis, which in 
further period led to faster growth. The major importers of Bulgarians pharmaceutical production 
are Russia, Romania, Croatia, Ukraine, Germany and Serbia. High level of export production, 
which is of a proper quality, provided Bulgarian pharmaceutical sector with additional 
investments for further reconstruction of already existing manufactures (Ministry of foreign 
affairs of Denmark, 2014). Therefore, we can make an assumption that in future Bulgaria might 
leave second group in a long time perspective. This is explained by the fact that pharmaceutical 
industry in this region seems to be favourable for investors worldwide. Latvia, Lithuania and 
Estonia (Baltic region in Eastern Europe) in terms of overall description can be grouped and 
described together, since the development of their pharmaceutical sector is similar. This region is 
renowned for highly developed biotechnological production, stable political and economic 
situation and high expenditure on R&D. Therefore, future development of Baltic States hugely 
depends on the level of budgeting and investment of pharmaceutical industry (Bitechnology in 
the Baltic States). 
Moving to the third group, one should state that this group differs from the previous ones 
significantly, since these countries are not in European Union, consequently, they have other 
governmental regulations for this sector. For instance, in Moldova, pharmaceutical regulations 
are often neglected. The main challenge for pharmaceutical sector in this region is lack of time to 
introduce necessary regulation functions and unwillingness of human resources to change 
(Ferrario, et al., 2014). Besides, even though there are 25 pharmaceutical manufacturing 
companies functioning in Moldova, only two of them are GMP certified, which consequently 
means that Moldova pharmaceutical companies are not competitive enough and cannot export 
production to many countries, which obligatory require GMP certification (Ministry of Health in 
collaboration with the World Health Organisation, 2011). Belorussian pharmaceutical market can 
be described as a stable one however; the capacity of the market is rather low, since it stands just 
on the 5 position among CIS countries. Despite of this, the growth of pharmaceutical sector in 
Belorussia in the end of 2013 resulted in 41%, which is the highest growth rate among CIS 
countries (Gorlova, 2014). This market is described by high presence of imported 
pharmaceuticals (e.g. in 2012, 69.4% of drugs were imported, whilst only 30.6% were produced 
by local representatives) (Belarus Pharmaceutical & Healthcare Industries Overview, 2017). 
Therefore, domestic output is currently highly motivated and supported by government (e.g. 
Joint ventures). However, international researchers state that in short run situation on 
pharmaceutical market in Belorussia will be rather pessimistic, which is supported by high 
inflation, increased economic and political instability, since Belarusian state is aligned from 
European Union regulations. On the other hand, Belarusian websites dedicated to pharmaceutical 
industry prove that currently there are 35 investment projects in pharmaceutical industry which 
are being put into operation (National Agency of Investment and Privatization, Republic of 
Belarus, 2015). Consequently, we can sum up that there is no clear understanding of 
pharmaceutical industry in Belorussia, since international resources state that the situation on the 
market is rather negative, whilst Belarusian agencies prove positive growth of pharmaceutical 
industry. Moving to Ukraine, which remains the second largest market in CIS (after Russia), we 
should state that under current unstable political situation, anti-terrorist operation in Eastern 
Ukraine, Crimea annexation and currency exchange instability, Ukrainian pharmaceutical 
industry suffers a lot and shows negative trends (Upharma: consulting healthcare, 2015). For 
instance, in January 2015 there was a positive tendency in the market in local currency, however, 
there was a negative dynamics in foreign currency (Ukrainian pharmaceutical market Sector 
study, 2016). Due to changes in GMP certification in the beginning of 2015, many 
pharmaceutical companies lost their positions. Besides, these changes are being implemented 
throughout 2015, due to harmonisation of Ukrainian laws with European Union regulations in 
pharmaceutical industry (the latest change was on 30 July 2015) (Association of international 
pharmaceutical manufactures, 2015). Besides, Ukrainian pharmaceutical market does not receive 
enough governmental expenditures and therefore outperform (only 4% are supported by the 
government, whilst in developed countries this indices has to be on a level of 76-80%, as in 
Germany, UK and France) (American Chamber of Commerce in Ukraine, 2015). Besides, the 
level of export of Ukrainian pharmaceutical production is far beyond its potential, even though 
major manufactures are working under GMP compliance. (American Chamber of Commerce in 
Ukraine, 2015) Consequently, we can notice that since pharmaceutical industry is under major 
transformations, it is complicated for both local and foreign bodies to show growth in their 
segment.  
Methodology 
This study adopts an interpretivist approach under epistemological path. Often, interpretivism 
philosophy is used for qualitative studies which are also referred as inductive, aiming to build a 
better theoretical perspective by using knowledge building approach. Qualitative research studies 
value social actors and emphasize their importance for the research (Saunders, et al., 2015). The 
purpose of qualitative research is to uncover views of individuals on the development of TQM in 
their companies. Moreover, qualitative analysis provides better understanding of the benefits and 
inhibiters of TQM implementation and gives explanation of how TQM is developed in Eastern 
Europe.  
This study involved data collection through 5 semi-structured interviews. These interviews were 
conducted with quality managers/ quality specialists working for pharmaceutical companies in 
Ukraine. The interviews were carried out in a following way. The potential respondents received 
e-mails with information regarding the purpose of the research, anonymity of responses and 
voluntary basis. The online link for the survey was included in order to distribute it among the 
colleagues. Out of more than 100 pharmaceutical companies randomly contacted in Eastern 
Europe, only 5 representatives agreed to provide answers to the open ended questions. In order to 
maintain the anonymity of the respondents, they are numbered from Respondent 1 to Respondent 
5. The respondents employ different job roles in the companies and therefore bring the view on 
TQM from different positions in the company, which is beneficial for the research. Besides, the 
size of company also varied, as well as the experience of the interviewees.   
Findings 
Despite all of the interviewees were aware of the fact that effective quality management 
influences success of the company directly, the results show that TQM in pharmaceutical 
industry in Eastern Europe is not well developed. In general, this can be verified by the fact that 
most of the interviewees could not explain TQM principles clearly, provide quality improvement 
plans and identify methods of quality control in their organisation. However, the similarity of the 
interviewee responses can be found among the inhibiters of TQM and weaknesses of TQM in 
pharmaceutical industry. To sum up, the results of 5 interviews show many similarities among 
different pharmaceutical companies in this region in terms of TQM. The detailed analysis of 
each section of the questions is provided below.  
Part 1 of the questions included general questions. The questions in this part provide information 
regarding the position of the interviewee in the company, size of the company, experience of the 
employee in this company and brief overview of quality certificates the company obtains. The 
results show that managers from different departments in different pharmaceutical companies 
were interviewed. The size of the company varied from middle-sized (101-500 employees) to 
large-sized (501 and more employees). Moreover, the interviewees were required to choose 
quality certification that their company obtains. The result shows that only one out of 5 
companies had quality certification ISO 9001. After this general information, more detailed data 
about TQM in the company was required, leading to part 2 of the interview questionnaire. 
In part 2, awareness of TQM principles, improvement plans and methods of quality control was 
explored. It has to be noticed that 4 out of 5 interviewees were aware of quality plans, which 
means that the company provides these plans and emphasizes on their importance for the 
company’s performance. Only two out of five interviewees admitted that they have long term 
and short term plans, whilst the rest of the respondents provided blurred answers. Moreover, 
Respondent 5 assumed that not all of the employees in his/her company are aware of the 
existence of such plans and also suggests more often reconsideration of quality plans which are 
designed on a one year basis. On the other hand, Respondent 1 stated that the company develops 
plans for quality improvement for 1 year, but also has short-term plans, ‘which are developed 
after every internal quality audit and meeting of Quality Council – once a month’. Therefore, we 
can conclude that pharmaceutical manufacturing companies in the same region treat quality plans 
in different ways, which directly influences their understanding of TQM. Moving to TQM 
principles awareness, we noticed that all of the respondents could name only ‘soft’ TQM 
principles, while it is significantly important for manufacturing companies to employ ‘hard’ 
TQM rules. From the responses we can see that methods are not well known by interviewees, 
since only two out of five could provide an opened answer and explain how they measure quality 
(‘consideration of achieved results’, ‘meeting with seniors to discuss achievements’). However, 
these methods are not the only ones which should be used by any organisation.  
In part 2 of the interview questionnaire, obstacles of TQM implementation in pharmaceutical 
industry and weaknesses of TQM development in Eastern Europe were explored. The results of 
the interviews provide similar responses regarding the inhibiters of TQM implementation thus 
answering vital questions for this research and meeting the objectives of the research. As an 
example, Respondent 1 states that the difficulties with TQM implementation rise due to limited 
understanding of different level of connection between the quality of the product and the 
performance of the company by managers’. Respondent 4 carries on, saying that the main 
weakness of TQM in Eastern Europe is lack of knowledge about TQM and linkage between 
quality improvement and its influence on organisation performance. Respondent 3 stated that 
lack of information among the employees leads to failure of successful TQM implementation. 
To sum up, the results of the interviews reveal the weak sides of TQM awareness in 
pharmaceutical industry in Eastern Europe and, by stating obstacles of TQM implementation we 
can see why these weaknesses occur. Improvement of communication regarding TQM between 
senior management and employees, as well as creating of a specialised role of TQM manager 
might improve current situation of TQM development in analysed region. 
Conclusions 
From the findings of the interviews, we can state that level of awareness of TQM and its 
principles has to be increased. In order to improve level of awareness of TQM in this region, the 
assessment of knowledge of managers in this sphere is required. Ishikawa (1985) states that the 
main emphasis of this assessment has to be given to senior managers, since they are the ones in 
the company who have to be aware about TQM trends. For example, Interviewee 5 considers 
that employees in the company are not aware of TQM and require further education; however, 
he/she states that senior managers might know about TQM, but they cannot see ‘beneficial side 
out of effective quality management’. Therefore, middle managers as to Ishikawa (1985) require 
better understanding of TQM in order to supply this knowledge to other employees in the 
company. Besides, it is crucial for middle managers to be aware not only of ‘soft’ TQM 
principles, but also ‘hard’. All 5 respondents while answering question 7 of the interview (Which 
TQM principles are employed in your organisation and since when. How TQM implementation 
influenced the performance of the company?) could state only ‘soft’ principles of TQM (e.g. 
constant improvement, orientation on consumer, specialised education, training programs). 
Nonetheless, all of the respondents are from pharmaceutical manufacturing sector and therefore 
should employ ‘hard’ TQM principles as well. 
This research contributes towards the analysis of current state of TQM, as well as provides 
understanding of the main TQM obstacles and drivers, which occur while implementing this 
method on the enterprises. Consequently, pharmaceutical companies will find the research useful 
due to the fact that it provides understanding of the main inhibiters of TQM and therefore will 
save managers time to underline the main problems. Moreover, overall employee understanding 
of TQM and its tools was provided, which leads to understanding whether further training 
programs regarding TQM, its principles and implementation are required. Moreover, theoretical 
part provides clearer understanding of ‘soft’ and ‘hard’ TQM principles. 
 
 
Limitations and Future Research 
One of the limitations of this research is that only one region was analysed. The researched 
focused only on Eastern European region. Due to time constrains, other regions were not 
explored. In case broader research in terms of region will be made in future, it will lead to clearer 
understanding of TQM in different regions. Consequently, it will enable to provide more 
examples of best practices which might be implemented in different regions. Moreover, the other 
limitation is the lack of data which was collected, since this region is described by high 
unwillingness to provide any kind of corporate information. In case more data was provided, the 
research could have been more exact. 
The research could have provided deeper understanding of TQM in this region in case more 
companies provided responses on survey and interview. However, due to high level of 
competition in pharmaceutical industry, the companies were not eager to provide in-depth 
information regarding TQM development. Therefore if more data was provided, the research 
could have been more exact.  
Future research will therefore focus on collecting more robust data and use other statistical 
techniques such as correlations, regressions, and structural equation modelling to arrive at a 
conclusion. Further analysis can also be made by comparison of the state of TQM in Eastern 
Europe and Western counterparts. Such analysis will lead to better understanding of the gap 
between these countries in terms of TQM implementation. Furthermore, such analysis will lead 
to creating new best practices for pharmaceutical companies in this region. This might also help 
to find similarities of TQM in different countries and therefore recommendations will expand on 
other countries as well 
 
References 
Al-Abri, R. and Al-Balushi, A., 2014. Patient satisfaction survey as a tool towards quality improvement. 
Oman medical journal, 29(1), p.3. 
American Chamber of Commerce in Ukraine, 2015. Country Porfile: Ukraine at a glance 2015, Available 
at: < http://www.chamber.ua/Content/Documents/593241790ACC_Country_Profile_2017_EN.pdf> 
(accessed 28/02/2018) 
Annual Report 2013 - PwC UK, Available < https://www.pwc.co.uk/assets/pdf/annual-report-2013.pdf> 
(accessed 28/02/2018). 
Association of international pharmaceutical manufactures, 2015. New laws in terms of GMP in Ukraine. 
Online. Available at: <http://aipm.org.ua/publikatsiyi/moz-ukrayini-zatverdzheno-novu-nastanovu-z-
gmp/> (accessed 28/02/2018) 
Belarus Pharmaceutical & Healthcare Industries Overview 2017. Available at < https://www.upharma-
c.com/en/news/175-Belarus-pharmaceutical-and-healthcare-report> (accessed 28/02/2018) 
Bhat, K. S., (010. Total Quality Management: Text & Cases. Bangalore: Himalaya Publishing House. 
Bilich, F. and Neto, A.A., 1997. Strategic Total Quality Management, pp. 88-89 
Bitechnology in the Baltic States. Online. Available at: <http://scanbalt.org/scanbalt-news/biotechnology-
baltic-states/> (accessed 28/02/2018) 
Brown, L., (2007). What your customers really want: seven qualities of customer care. Supervision, 68(6), 
pp. 20-21. 
CHEManager International, 2013. Russia’s and Eastern Europe’s Booming Pharma Industry. Online. 
Available at: http://www.chemanager-online.com/en/topics/pharma-biotech-processing/russia-s-and-
eastern-europe-s-booming-pharma-industry [28th February 2018] 
Chen, C. H., Chong, Y. T., Chang, W., & Yan, W. 2012. A quality–time–cost-oriented strategy for 
product conceptualization. Advanced Engineering Informatics, 26(1), pp. 16-25. 
Chen, C. M. 2017. Exploring the Mediated and Moderated Effects of Operator Service Quality on 
Customer Retention: Evidence from Taiwan’s Mobile Market. Journal of Management Research, 9(4), 
21-42. 
Dale, B. G. and Cooper, C. L. 1994. Introducing TQM: The Role of Senior Management, Management 
Decision, 32 (1), pp.20-26, 
Elliott, K.M., 2015. Total Quality Management: A New Paradigm that should Enhance Marketing 
Education. In Proceedings of the 1994 Academy of Marketing Science (AMS) Annual Conference (pp. 
413-416). Springer, Cham. 
European Comission, 2015. Country Report Slovakia 2015, Brussels, Avilable at 
<https://ec.europa.eu/info/publications/2015-european-semester-country-reports_en> (accessed 
28/02/2018) 
Ferrario, A., Sautenkova, N., Bezverhni, Z., Seicas, R., Habicht, J., Kanavos, P. and Safta, V., 2014. An 
in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of pharmaceutical 
policy and practice, 7(1), p.4. 
Flynn, B.B., Schroeder, R.G. and Sakakibara, S., 1994. A framework for quality management research 
and an associated measurement instrument. Journal of Operations management, 11(4), pp.339-366. 
Fotopoulos, C.B. and Psomas, E.L., 2009. The impact of “soft” and “hard” TQM elements on quality 
management results. International Journal of Quality & Reliability Management, 26(2), pp.150-163. 
Garvin, D. A. 1984. What Does “hltoduct Quality” Really Mean?. Sloan management review, pp. 25. 
Garza-Reyes, J. A., Yu, M., Kumar, V., & Upadhyay, A. 2018. Total quality environmental management: 
Adoption status in the Chinese manufacturing sector. The TQM Journal, 30(1), pp. 2-19. 
Ghobadian, A., & Gallear, D. 1997. TQM and organization size. International journal of operations & 
production management, 17(2), pp. 121-163. 
Gorlova, I., 2014. Overview of Ukrainian pharmaceutical market. Available at : 
<http://docplayer.net/51140031-Overview-of-ukrainian-pharmaceutical-market-gorlova-irina-ceo.html> 
(accessed 28/02/2018) 
Haleem, Reham M., Maissa Y. Salem, Faten A. Fatahallah, and Laila E. Abdelfattah. "Quality in the 
pharmaceutical industry–A literature review." Saudi Pharmaceutical Journal 23, no. 5 (2015): 463-469. 
Heravizadeh, M., Mendling, J., & Rosemann, M. 2008. Dimensions of business processes quality 
(QoBP). In International Conference on Business Process Management, pp. 80-91, Springer, Berlin, 
Heidelberg. 
Hill, S., & Wilkinson, A. 1995. In search of TQM. Employee Relations, 17(3), 8-25. 
Ho, S. K. (2010). Integrated lean TQM model for global sustainability and competitiveness. The TQM 
Journal, 22(2), 143+-158. 
Hoyle, D., 2007. Quality Management Essentials. 1 iss. Routledge. 
Imeri, S. and Kekäle, T., 2013. Towards an understanding of the impact of TQM in firms in south east 
europe–a qualitative approach. Business Excellence and Management, 3(3), pp.1-17. 
Invest Slovenia, 2012. Chemicals and Pharmaceuticals: key figures 2012. [Online.]  
Available at:< http://www.investslovenia.org/industries/chemicals-pharmaceuticals/> (accessed 
28/02/2018) 
Ishikawa, K., 2012, What is Total Quality Control?: The Japanese Way, Prentice Hall- Michigan 
Jablonski, F., 2007. The Hungarian Pharmaceutical Industry Is Highly Sophisticated. [Online.]  
Available at: http://www.process-worldwide.com/control-and-automation/articles/296468/ (accessed 
28/02/2018) 
Juran, J., & Godfrey, A. B. 1999. Quality handbook. Republished McGraw-Hill, pp. 173-178. 
Keng Boon, O., Arumugam, V., & Seng Hwa, T. 2005. Does soft TQM predict employees’ attitudes?. 
The TQM Magazine, 17(3), pp. 279-289. 
Kia Liang Tan, P., 1997. An evaluation of TQM and the techniques for successful implementation. 
Training for Quality, 5(4), pp.150-159. 
Lawson, R., 2008. Measuring company quality. The Journal of Investing, 17(4), pp.38-55. 
Luburić, R., 2014. Total Quality Management as a paradigm of business success. Journal of Central 
Banking Theory and Practice, 3(1), pp.59-80. 
Madu, C.N. and Kuei, C.H., 1993. Dimensions of quality teaching in higher institutions. Total Quality 
Management, 4(3), pp.325-338. 
Mann, R. and Kehoe, D., 1994. An evaluation of the effects of quality improvement activities on business 
performance. International Journal of Quality & Reliability Management, 11(4), pp.29-44. 
McKinsey & Company, 2015. Poland 2025: Europe's new growth engine, Avilable at 
<https://www.mckinsey.com/~/media/mckinsey/business%20functions/economic%20studies%20temp/ou
r%20insights/how%20poland%20can%20become%20a%20european%20growth%20engine/poland%202
025_full_report.ashx> (accessed 28/02/2018) 
Ministry of foreign affairs of Denmark, 2014. Pharmaceutical and Healthcare sector Bulgaria. Available 
at < bulgarien.um.dk/~/media/.../Pharmaceutics%20and%20Healthcare_2014.pdf?la=en> (accessed 
28/02/2018) 
Mitra, A. (2016). Fundamentals of quality control and improvement. John Wiley & Sons, New 
Jersey. 
Mohammad Mosadeghrad, A., 2013. Obstacles to TQM success in health care systems. International 
Journal of Health Care Quality Assurance, 26(2), pp.147-173. 
Núñez, A. G., del Carmen Penadés, M., Canós, J. H., & Borges, M. R. (2015). Towards a Total Quality 
Framework for the Evaluation and Improvement of Emergency Plans Management. In ISCRAM. 
Kristiansand, May 24-27 Palen, Büscher, Comes & Hughes, eds. 
Oakland, J. S., 2014. Total Quality Management: Text With Cases 4e: Text with Cases. 4: Routledge 
Oliveira, G. S., Corrêa, J. E., Balestrassi, P. P., Martins, R. A., & Turrioni, J. B. 2017. Investigation of 
TQM implementation: empirical study in Brazilian ISO 9001-registered SMEs. Total Quality 
Management & Business Excellence, pp. 1-19. 
Ouyang, L. Y., Chen, C. K., & Chang, H. C. 2002. Quality improvement, setup cost and lead-time 
reductions in lot size reorder point models with an imperfect production process. Computers & 
Operations Research, 29(12), pp. 1701-1717. 
Porter, M. E. 1980. Industry structure and competitive strategy: Keys to profitability. Financial Analysts 
Journal, 36(4), 30-41. 
PR NewsWire, 2012. The Outlook for Pharmaceuticals in Central & Eastern Europe. [Online.]  
Available at: http://www.prnewswire.com/news-releases/the-outlook-for-pharmaceuticals-in-central--
eastern-europe-183334411.html (accessed 28/02/2018) 
Prajogo, D. I., & Sohal, A. S. 2006. The relationship between organization strategy, total quality 
management (TQM), and organization performance––the mediating role of TQM. European journal of 
operational research, 168(1), pp. 35-50. 
Psomas, E. L., & Jaca, C. 2016. The impact of total quality management on service company 
performance: evidence from Spain. International Journal of Quality & Reliability Management, 33(3), 
pp. 380-398. 
Psomas, E. L., & Jaca, C. 2016. The impact of total quality management on service company 
performance: evidence from Spain. International Journal of Quality & Reliability Management, 33(3), 
pp. 380-398. 
Psomas, E., Vouzas, F., Bouranta, N. and Tasiou, M., 2017. Effects of total quality management in local 
authorities. International Journal of Quality and Service Sciences, 9(1), pp.41-66. 
Rahman, S.U. and Bullock, P., 2005. Soft TQM, hard TQM, and organisational performance 
relationships: an empirical investigation. Omega, 33(1), pp.73-83.. 
Ross, J. E. (2017). Total quality management: Text, cases, and readings. Routledge. London 
Saunders, M., Lewis, P. & Thornhill, A., 2015. Research Methods for Business Students. Financial 
Times/ Prentice Hall; 7
th
 edition. 
Seiter, A., 2010. A practical approach to pharmaceutical policy. World Bank Publications. 
Shanley, A., 2005. Operational excellence: walking the talk, Available at 
<http://www.pharmamanufacturing.com/articles/2005/400.html> (accessed 28/02/2018). 
Srinidhi, B., 1998. Strategic quality management. International Journal of Quality Science, 3(1), pp.38-
70. 
Steenkamp, J. B. E. 1990. Conceptual model of the quality perception process. Journal of Business 
research, 21(4), pp. 309-333. 
Terziovski, M., Sohal, A., & Moss, S. 1999. Longitudinal analysis of quality management practices in 
Australian organizations. Total Quality Management, 10(6), pp. 915-926. 
Ukrainian pharmaceutical market Sector study, 2016, Available at: < 
http://www.iberglobal.com/files/2016-2/ucrania_farmaceutico.pdf> (accessed 28/02/2018) 
Upharma: consulting healthcare, 2015. Available at: < http://upharma-c.com/en/news/takeda/?page=13> 
(accessed 28/02/2018) 
Visser, W., Matten, D., Pohl, M., & Tolhurst, N. 2010. The A to Z of corporate social responsibility. John 
Wiley & Sons. 
Vora, M. K. (2002). Business excellence through quality management. Total Quality Management, 13(8), 
pp. 1151-1159. 
Vouzas, F. and Psychogios, A.G., 2007. Assessing managers' awareness of TQM. The TQM Magazine, 
19(1), pp.62-75. 
Woodcock, J., 2004. The concept of pharmaceutical quality. Am Pharm Rev, 7(6), pp.10-15. 
Ye, G. and Mukhopadhyay, S.K., 2013. Role of demand-side strategy in quality competition. 
International Journal of Production Economics, 145(2), pp.696-701. 
Youssef, M. A., & Youssef, E. M. 2018. The Synergistic Impact of ISO 9000 and TQM on Operational 
Performance and competitiveness. International Journal of Quality & Reliability Management, (just-
accepted), 00-00. 
Zairi, M., 1994. Leadership in TQM implementation: some case examples. The TQM Magazine, 6(6), 
pp.9-16. 
